Drug Pricing Back in the Spotlight

July 21, 2020

Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?

Payer Contracting: Three Criteria for Success

April 18, 2020

Bill Barr outlines the systematic application of three criteria to guide discounting decisions.

Is ICER’s Speed Coming at the Expense of Credibility?

March 19, 2020

The rapid pace of new pharmaceutical approvals raises questions of whether ICER can keep up and maintain the quality and rigor demanded by healthcare audiences, writes Jeremy Schafer.

Changing Top Trends in Health Economics and Operational Research

January 20, 2020

ISPOR has published its third issue of the top trends in HEOR. Leela Barham takes a look at how the list has changed over time.

International Price Referencing: Stacking the Deck with Lower Income Economies

December 09, 2019

Pharmaceutical Executive

This article discusses how cost differences with other countries reflect income differences, how these differences are typical for cost in medical services, and more.

Is Pharma Losing the Centerpiece of Its Market Access Toolbox?

December 02, 2019

With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.

Can Global Innovation in Oncology be Sustained in the Face of Price Controls?

November 21, 2019

Pricing in the context of patient access and affordability continues to present problems and constitute a real threat to innovation. Meaningful reform involves rectifying market imperfections in public and private third-party prescription drug payment sectors, writes Robert A. Freeman.

Trends in Payer Reliance on ICER Assessments

November 13, 2019

In response to growing Institute for Clinical and Economic Review (ICER) activity, Jenny Lee and Eric Latch take a revised look at payer reliance on ICER assessments and perceptions on value-based pricing.

The Quest to Measure Drug Effectiveness

November 08, 2019

Pharmaceutical Executive

A formal effort is underway in Europe to gather concrete clues on the value of real-world evidence in payer decision-making.

Validating Value Data: AI and Outcomes

October 08, 2019

Pharmaceutical Executive

Realizing the full potential of enabling technologies such as AI and machine learning in measuring treatment value and outcomes.